Aligos Therapeutics Inc —— 季度财务数据 (NASDAQ:ALGS) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

经营活动产生的现金 -18.4 M-20.91 M-15.5 M-24.34 M-21.75 M -82.5 M 投资活动产生的现金 19.97 M-44.07 M-39.42 M47.68 M-2.02 M -37.83 M 融资活动产生的现金 97 K101.74 M-177 K-53 K123 K 101.64 M 自由现金流 -18.4 M-20.91 M-15.5 M-24.34 M-21.75 M -82.5 M

新闻

H.C. Wainwright维持Aligos Therapeutics股票买入评级，看好pevifoscorvir研发进展

Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress

Aligos Therapeutics股价因乙肝二期研究进展而上涨

Aligos Therapeutics stock rises on Phase 2 HBV study progress

Aligos公布乙肝药物二期研究进展

Aligos reports progress on Phase 2 hepatitis B drug study

Aligos Therapeutics任命James Hassard为首席商务官

Aligos therapeutics appoints James Hassard as chief commercial officer

UBS以肝脏疾病管线为由给Aligos Therapeutics股票首次评级为"买入"

Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline

Aligos报告THR-β激动剂协同减重效果

Aligos reports synergistic weight loss effect with THR-β agonist